Lilly\'s CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint\, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer